Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) – Pipeline Review, H2 2017’, provides in depth analysis on Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Oncology, Women's Health, Metabolic Disorders, Dermatology, Immunology and Male Health under development targeting Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2)

The report reviews Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics and enlists all their major and minor projects

The report assesses Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Acadia Pharmaceuticals Inc

AstraZeneca Plc

Atossa Genetics Inc

Chamaeleo Pharma NV

Eli Lilly and Company

Endece LLC

EndoCeutics Inc

Karo Pharma AB

Kissei Pharmaceutical Co Ltd

MEI Pharma Inc

Mithra Pharmaceuticals SA

Oasmia Pharmaceutical AB

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Overview 7

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 13

Products under Development by Universities/Institutes 16

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Therapeutics Assessment 18

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Companies Involved in Therapeutics Development 23

Acadia Pharmaceuticals Inc 23

AstraZeneca Plc 23

Atossa Genetics Inc 23

Chamaeleo Pharma NV 24

Eli Lilly and Company 24

Endece LLC 25

EndoCeutics Inc 25

Karo Pharma AB 26

Kissei Pharmaceutical Co Ltd 26

MEI Pharma Inc 27

Mithra Pharmaceuticals SA 27

Oasmia Pharmaceutical AB 28

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Drug Profiles 29

(acolbifene hydrochloride + prasterone) - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

AC-186 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

acolbifene hydrochloride - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

acolbifene hydrochloride + GnRH Agonist + prasterone - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

AUS-131 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Drug to Agonize ER-Beta for Multiple Sclerosis and Neurodegenerative Diseases - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

erteberel - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Estetrol - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

fosfestrol - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

fulvestrant - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

fulvestrant - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

KB-3944 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

KB-9520 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Loseasonique - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

NDC-1308 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

NDC-1352 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Small Molecule to Agonize ESR2 for Obesity and Depression - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Small Molecules to Agonize Estrogen Beta Receptor for Oncology and Inflammatory diseases - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

SR-16234 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

sulfestrol - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Dormant Products 59

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Discontinued Products 62

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) - Product Development Milestones 63

Featured News & Press Releases 63

Sep 01, 2017: NICE says benefits of breast cancer drug fulvestrant too uncertain to make it cost effective 63

Aug 28, 2017: Faslodex receives US FDA approval as monotherapy for expanded use in breast cancer 63

Jul 26, 2017: Faslodex receives EU approval as first-line therapy for advanced breast cancer 64

Jul 25, 2017: Atossa Genetics Provides Update on Fulvestrant Microcatheter Phase 2 Study 65

Jul 06, 2017: Mithra Strengthens E4 Patent Position in Australian Market 65

Jun 23, 2017: Faslodex (fulvestrant) receives positive CHMP opinion for use in 1st-line hormone receptor-positive advanced breast cancer 66

Jun 21, 2017: Mithra Completes Recruitment For Additional Estelle Safety Study 66

Jun 09, 2017: Mithra Receives Orphan Drug Designation From EMA For E4 In Neonatal Encephalopathy 67

May 09, 2017: Atossa Genetics Receives Approval from Institutional Review Board for Continuation of its Fulvestrant Microcatheter Phase 2 Study 67

Feb 13, 2017: ENDECE Opens San Francisco Office 68

Jan 18, 2017: Mithra Announces US Patent Allowance for the Use of Estetrol as Emergency Contraceptive 68

Jan 12, 2017: Mithra’s North American Advisory Board For Donesta to Meet In Miami, Florida 69

Jan 09, 2017: Atossa Genetics Provides Update on its Phase 2 Study of Fulvestrant Administered with its Microcatheter 69

Dec 08, 2016: AstraZeneca Announces Subgroup Analysis from FALCON Trial Comparing FASLODEX (fulvestrant) to ARIMIDEX (anastrozole) 70

Nov 29, 2016: AstraZeneca Provides Update on Faslodex at The 2016 San Antonio Breast Cancer Symposium, 6-10 December 2016, San Antonio, USA 71

Appendix 72

Methodology 72

Coverage 72

Secondary Research 72

Primary Research 72

Expert Panel Validation 72

Contact Us 72

Disclaimer 73

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indications, H2 2017 10

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12

Number of Products under Development by Companies, H2 2017 13

Products under Development by Companies, H2 2017 14

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15

Number of Products under Investigation by Universities/Institutes, H2 2017 16

Products under Investigation by Universities/Institutes, H2 2017 17

Number of Products by Stage and Mechanism of Actions, H2 2017 19

Number of Products by Stage and Route of Administration, H2 2017 21

Number of Products by Stage and Molecule Type, H2 2017 22

Pipeline by Acadia Pharmaceuticals Inc, H2 2017 23

Pipeline by AstraZeneca Plc, H2 2017 23

Pipeline by Atossa Genetics Inc, H2 2017 24

Pipeline by Chamaeleo Pharma NV, H2 2017 24

Pipeline by Eli Lilly and Company, H2 2017 25

Pipeline by Endece LLC, H2 2017 25

Pipeline by EndoCeutics Inc, H2 2017 25

Pipeline by Karo Pharma AB, H2 2017 26

Pipeline by Kissei Pharmaceutical Co Ltd, H2 2017 26

Pipeline by MEI Pharma Inc, H2 2017 27

Pipeline by Mithra Pharmaceuticals SA, H2 2017 27

Pipeline by Oasmia Pharmaceutical AB, H2 2017 28

Dormant Products, H2 2017 59

Dormant Products, H2 2017 (Contd..1), H2 2017 60

Dormant Products, H2 2017 (Contd..2), H2 2017 61

Discontinued Products, H2 2017 62

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Top 10 Indications, H2 2017 10

Number of Products by Mechanism of Actions, H2 2017 18

Number of Products by Stage and Mechanism of Actions, H2 2017 18

Number of Products by Routes of Administration, H2 2017 20

Number of Products by Stage and Routes of Administration, H2 2017 20

Number of Products by Stage and Molecule Type, H2 2017 22

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports